WuXi XDC Cayman, Inc. (HK:2268)
:2268
Want to see HK:2268 full AI Analyst Report?
2268 Stock Chart & Stats
HK$54.80
HK$1.55(5.24%)
At close: 4:00 PM EST
HK$54.80
HK$1.55(5.24%)
Day’s Range― - ―
52-Week RangeHK$38.80 - HK$85.50
Previous CloseN/A
Volume4.11M
Average Volume (3M)6.66M
Market Cap
HK$60.51B
Enterprise ValueHK$59.13B
Total Cash (Recent Filing)HK$7.47B
Total Debt (Recent Filing)HK$879.52M
Price to Earnings (P/E)37.5
Beta1.12
Next Earnings
Aug 25, 2026EPS Estimate
0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.20
Shares Outstanding1,260,609,400
10 Day Avg. Volume10,688,598
30 Day Avg. Volume6,656,062
Financial Highlights & Ratios
PEG Ratio1.31
Price to Book (P/B)6.72
Price to Sales (P/S)12.13
P/FCF Ratio113.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$81.58Price Target Upside48.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)1.62
Revenue Forecast (FY)HK$8.14B
Bulls Say, Bears Say
Bulls Say
Revenue Growth MomentumSustained revenue growth (13.8% YoY to 5.79B in 2025) indicates successful commercial adoption of ADC services and expanding customer programs. Over 2–6 months this durable top-line momentum supports capacity utilization, scale economics, and attractiveness to late-stage clients.
High Profitability And MarginsRobust operating and net margins reflect pricing power and efficiency in specialized ADC CDMO services. These healthy margins provide durable internal funding for capex and R&D, supporting competitive differentiation and reinvestment even through medium-term cycles.
Conservative Balance SheetVery low leverage and substantial equity provide financial flexibility to fund GMP capacity and absorb program timing variability. A conservative balance sheet reduces refinancing risk and supports capital deployment for durable growth or opportunistic M&A over months to years.
Bears Say
Inconsistent Cash ConversionVolatile free cash flow and weak conversion (FCF ~34% of net income in 2025) indicate that earnings do not reliably become discretionary cash. Over the medium term this constrains organic funding for capex, raises working-capital sensitivity, and limits predictable reinvestment or distributions.
Margin Compression TrendYear-over-year margin compression suggests rising cost intensity or mix shifts as the company scales. If structural, this could erode return on invested capital and require sustained pricing power or efficiency actions to restore historical profitability over the next several quarters.
Dependence On ADC Program Demand And UtilizationBusiness performance is structurally tied to customers' ADC program timing and facility utilization. Delays, program failures, or weak demand directly reduce revenue and underutilize expensive GMP capacity, creating persistent cyclicality and execution risk over the medium term.
WuXi XDC Cayman, Inc. News
2268 FAQ
What was WuXi XDC Cayman, Inc.’s price range in the past 12 months?
WuXi XDC Cayman, Inc. lowest stock price was HK$38.80 and its highest was HK$85.50 in the past 12 months.
What is WuXi XDC Cayman, Inc.’s market cap?
WuXi XDC Cayman, Inc.’s market cap is HK$60.51B.
When is WuXi XDC Cayman, Inc.’s upcoming earnings report date?
WuXi XDC Cayman, Inc.’s upcoming earnings report date is Aug 25, 2026 which is in 69 days.
How were WuXi XDC Cayman, Inc.’s earnings last quarter?
WuXi XDC Cayman, Inc. released its earnings results on Mar 23, 2026. The company reported HK$0.699 earnings per share for the quarter, missing the consensus estimate of HK$0.711 by -HK$0.011.
Is WuXi XDC Cayman, Inc. overvalued?
According to Wall Street analysts WuXi XDC Cayman, Inc.’s price is currently Undervalued.
Does WuXi XDC Cayman, Inc. pay dividends?
WuXi XDC Cayman, Inc. does not currently pay dividends.
What is WuXi XDC Cayman, Inc.’s EPS estimate?
WuXi XDC Cayman, Inc.’s EPS estimate is 0.89.
How many shares outstanding does WuXi XDC Cayman, Inc. have?
WuXi XDC Cayman, Inc. has 1,260,609,400 shares outstanding.
What happened to WuXi XDC Cayman, Inc.’s price movement after its last earnings report?
WuXi XDC Cayman, Inc. reported an EPS of HK$0.699 in its last earnings report, missing expectations of HK$0.711. Following the earnings report the stock price went down -4.06%.
Which hedge fund is a major shareholder of WuXi XDC Cayman, Inc.?
Currently, no hedge funds are holding shares in HK:2268
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
WuXi XDC Cayman, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
226.79%
12-Months-Change
Fundamentals
Return on Equity
16.29%
Trailing 12-Months
Asset Growth
65.58%
Trailing 12-Months
Company Description
WuXi XDC Cayman, Inc.
WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.
2268 Stock 12 Month Forecast
Average Price Target
HK$81.58
▲(48.87% Upside)
Technical Analysis
Wuxi Biologics (Cayman)
―
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Pharmaron Beijing Co., Ltd. Class H
―
WuXi AppTec Co., Ltd. Class H
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---